Latanja Bettis
Family · Atmore, ALNPI 1780810622
Payments from drug & device makers
Across 65 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$196
- AbbVie$165
- AstraZeneca$139
- Novo Nordisk$74
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$55
- Bayer$54
- plus $492 from 19 others
What the payments were for
- Food & beverage$1,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $196 |
| AbbVie | 9 | $165 |
| AstraZeneca(2 entities) | 7 | $139 |
| Novo Nordisk | 5 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Bayer | 3 | $54 |
| Biogen | 2 | $53 |
| Lilly USA, LLC | 3 | $45 |
| Pfizer | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $38 |
| GSK | 2 | $37 |
| Boehringer Ingelheim | 2 | $33 |
| Atland Pharmaceuticals, LLC | 1 | $31 |
| Dexcom, Inc. | 2 | $31 |
| Ardelyx, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Viiv Healthcare Company | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
How this compares
$1,174 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $30,644 |
| MounjaroTirzepatide | 23 | $29,428 |
| JardianceEmpagliflozin | 11 | $14,593 |
| EliquisApixaban | 12 | $12,810 |
| XareltoRivaroxaban | 19 | $9,142 |
| Omeprazole | 67 | $1,499 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $1,437 |
| Triamcinolone Acetonide | 21 | $1,353 |
| Levothyroxine Sodium | 95 | $1,347 |
| Megestrol Acetate | 20 | $1,341 |
| Atorvastatin Calcium | 105 | $895 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $831 |
| Fluticasone Propionate | 46 | $823 |
| Metformin Hcl | 88 | $747 |
| Pravastatin Sodium | 58 | $746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $74 | $30,64430 claims |
| Lilly USA, LLCMounjaro | $45 | $29,42823 claims |
| Boehringer IngelheimJardiance | $33 | $14,59311 claims |
| PfizerEliquis | $41 | $12,81012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.
Other family in Atmore
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.